HLL Biotech Limited on 31 August 2013 entered into a long-term supply and technology transfer agreement with the Institute of Immunology, Zagreb, Croatia. The agreement was made to initiate mass production of measles vaccine in India.
Under the newly signed agreement, HLL Lifecare Limited will produce 80 million doses of measles vaccine, for the Indian market, which will meet a major share of the Government requirements.
This partnership would also result in development of the next generation vaccines. To house the technical support and bring it into use, the HLL Lifecare has begun the construction work on Hindustan Biotech’s Integrated Vaccine Complex at Chengalpet in Tamil Nadu at an investment of 594 crore rupees. It is predicted that the new Vaccine Complex would become fully operative by the end of 2016.
HLL Biotech Limited is a subsidiary of Central Public Sector Miniratna Company, HLL Lifecare Limited.
HLL Lifecare Limited
HLL Lifecare Limited is a Government of India enterprise and is generally known as a condom and contraceptives manufacturing company. After completing about than 30 years of consistent quality performance, HLL Lifecare has now tmoved on to take bigger responsibilities like – vaccine security of the nation.
Who: HLL Biotech
When: August 2013
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.